THE TGA has issued a safety
advisory on ‘risk factors for
bleeding’ in relation to the newly
PBS-listed novel anticoagulants
which include Eliquis (apixaban),
Pradaxa (dabigatran) and Xarelto
(rivaroxaban).
The TGA said that with use of
these medicines likely to increase
it is timely to remind health
professionals of the need to
“carefully consider each patient’s
risk factors for bleeding” when
prescribing the products.
“Clinical trials and post marketing
experience have shown that major
bleeding events, including those
leading to death, have occurred
with all of these products,” with the
TGA urging renal function tests and
consideration of a range of bleeding
risk factors when considering NoACs.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Sep 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Sep 13
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.